Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report sent to investors on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, February 26th.

Minerva Neurosciences Trading Up 2.1 %

NERV opened at $1.73 on Tuesday. The firm has a market cap of $12.10 million, a price-to-earnings ratio of -3.93 and a beta of 0.10. Minerva Neurosciences has a 12 month low of $1.42 and a 12 month high of $3.69. The stock has a fifty day moving average price of $1.96 and a 200-day moving average price of $2.27.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.49. On average, equities research analysts forecast that Minerva Neurosciences will post -0.3 EPS for the current year.

Institutional Trading of Minerva Neurosciences

An institutional investor recently raised its position in Minerva Neurosciences stock. Citadel Advisors LLC lifted its stake in Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,764 shares of the biopharmaceutical company’s stock after buying an additional 8,525 shares during the quarter. Citadel Advisors LLC owned approximately 0.37% of Minerva Neurosciences worth $57,000 as of its most recent SEC filing. Institutional investors own 34.56% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.